Radiopharmaceutical needed for prostate cancer patient with metastatic lesions after definite treatment
Ended Awarded Last action
- Contract number
- HT009026FG1210062
- Awardee
-
Sofie CO. UEI JV1AHJHGUGG3
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $25,261
Award facts
- Contract value 100% obligated
- $25,261.04 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6640 Laboratory Equipment And Supplies
- Set-aside
- No set-aside
- Competition
- 2 offers Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Sterling, VA, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Health Agency awarded Sofie CO. (doing business as IBA Molecular) a $25,261.04 firm fixed-price call under an existing blanket purchase agreement on December 2, 2025, for radiopharmaceutical delivery supporting prostate cancer imaging in patients with metastatic lesions following definitive treatment. The contract, which carries no set-aside designation, will be performed in Sterling, Virginia, with an ultimate completion date of September 30, 2026. This award represents a task order issued against the Defense Health Agency's $6.5 million master blanket purchase agreement for pharmaceutical supplies, under which Sofie CO. provides specialized radiopharmaceuticals to military treatment facilities across the Defense Health System.
Sofie CO. is a subsidiary of Sofie Biosciences headquartered in Sterling, Virginia, and specializes in the development and manufacturing of molecular diagnostics and therapeutic radiopharmaceuticals for cancer detection and neurological imaging. The company maintains an established track record as a federal healthcare vendor, supplying critical PET imaging agents including PYLARIFY (piflufolastat F-18) for prostate cancer detection, NEURACEQ for Alzheimer's disease imaging, and various gallium and copper-based radiopharmaceuticals to the Department of Veterans Affairs, Defense Health Agency, and National Institutes of Health. This contract supports the Defense Health Agency's mission to deliver specialized diagnostic imaging capabilities to military personnel, veterans, and their families through the nation's military treatment facility network.
Quick answers
Who was awarded contract HT009026FG1210062?
HT009026FG1210062 was awarded to Sofie CO. by Defense Health Agency (Department of Defense) on December 2, 2025.
How much is contract HT009026FG1210062 worth?
The government has obligated $25,261 on HT009026FG1210062.
Is contract HT009026FG1210062 an order under another contract?
Yes. HT009026FG1210062 is a BPA call under HT001424A0002, a blanket purchase agreement.
Was contract HT009026FG1210062 competed?
The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award